ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1390

Chaperonin Protein 14-3-3n (eta) In Rheumatoid Arthritis and Arthritogenic Viral Infections

Stanley J. Naides, Olga S Zhukov, Rania W Abolhosn and Joanna M Popov, Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Diagnostic Tests, rheumatoid arthritis (RA) and viruses

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: The 14-3-3 proteins are ubiquitously-expressed intracellular chaperonins. Expression of the η (eta) isoform is restricted to synovial and CNS tissues. Extracellular 14-3-3η induces proinflammatory MAPK and NFkB cascades in THP-1 cells in vitro. Extracellular 14-3-3η has been proposed as a novel biomarker for joint damage in rheumatoid arthritis (RA) and psoriatic arthritis, with serum elevation occurring in early RA. 14-3-3η positivity may add diagnostic sensitivity to laboratory RA markers such as rheumatoid factor (RF) and citrullinated cyclic peptide antibody (CCP). However, 14-3-3η expression in arthritogenic viral infection has not been studied. The aim of this study was to determine the frequency of elevated 14-3-3η in patients with RA and in those with HCV, acute EBV, or acute B19 infections.

Methods: We developed a quantitative 14-3-3η sandwich ELISA and verified the reference range using 134 serum specimens from healthy donors (67 males, 67 females; ages 18-65). 14-3-3η was measured in de-identified residual clinical specimens originally submitted for routine RA or infectious disease diagnostic testing.

Results:

The 14-3-3η 95th-percentile reference range was defined as <0.2 ng/mL and the reportable range was <0.2 to >20.0 ng/mL. Six healthy subjects (4%) had elevated 14-3-3η levels; 2 of them were weakly RF positive. RF+/CCP+ subjects had the highest frequency of elevated 14-3-3η (56%) and the highest 14-3-3η median level (Table). Frequency of elevated 14-3-3η was lower in the RF+/CCP- and virus-infected groups.. None of the RF-/CCP+ subjects had elevated 14-3-3η, but the number of subjects was small (n=10). The frequency of elevated 14-3-3η in the RF-/CCP- group was 5%. Of 23 subjects with elevated 14-3-3η in the HCV group, 1 was RF+/CCP+, 13 RF+/CCP-, and 9 RF-/CCP-. Of 6 subjects with elevated 14-3-3η in the EBV group, 1 was RF+/CCP+, 2 RF+/CCP-, and 3 RF-/CCP+. All 5 subjects with elevated 14-3-3η in the B19 group were RF-/CCP-.

Subject Group

n

Number with Elevated 14-3-3η (%)

Median Abnormal 14-3-3η Value (Interquartile Range) (ng/mL)

Healthy

134

6 (4%)

1.19 (0.66-4.61)

RF+/CCP+

43

24 (56%)

4.37 (0.66-8.24)

RF+/CCP-

131

20 (15%)

0.73 (0.39-1.15)

RF-/CCP+

10

0 (0%)

NA

RF-/CCP-

305

14 (5%)

0.54 (0.33-0.73)

HCV (RIBA)+

162

23 (14%)

0.46 (0.29-1.21)

EBV VCA IgM+

101

17 (17%)

0.44 (0.33-1.54)

B19 IgM+

34

5 (15%)

0.26 (0.20-0.72)

Conclusion: 14-3-3η elevation was most frequent among patients with RF+/CCP+ results (consistent with an RA diagnosis). The data suggest that RA and some HCV, EBV, and parvovirus B19 infections may share pathogenetic mechanisms characterized by synovial release of 14-3-3η. Of note, the median abnormal 14-3-3η level was higher in the RF+/CCP+ group than in the virus-infected groups. This suggest less synovitis in viral arthritis than in RA, consistent with clinical observations.


Disclosure:

S. J. Naides,

Quest Diagnostics,

3;

O. S. Zhukov,

Quest Diagnostics,

3;

R. W. Abolhosn,

Quest Diagnostics,

3;

J. M. Popov,

Quest Diagnostics,

3.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/chaperonin-protein-14-3-3n-eta-in-rheumatoid-arthritis-and-arthritogenic-viral-infections/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology